×
BRCA1/2 and CHEK2 mutation prevalence in patients with breast and/or ovarian cancer in the South of Russia.
https://meetinglibrary.asco.org/record/188807
Natalia A. Petrusenko

May 28th, 2020 - Background: The development of breast cancer (BC) and ovarian cancer (OC), as well as their chemoresistance may be due to the presence of mutations in many genes, but most often in BRCA1/2 and CHEK2. Early diagnosis and subsequent preventive interventions improve the survival of patients with mutations in the BRCA1/2 genes. Genotyping of the gene inactivation events predicts a high sensitivity ...

Effect of inhibition of receptor tyrosine kinase AXL by a selective small molecular inhibitor R428 (BGB321) on DNA damage repair response in ovarian cancer cells.
https://meetinglibrary.asco.org/record/188622
Ruby Yun-Ju Huang, MD, PhD

May 28th, 2020 - Background: AXL is a receptor tyrosine kinase that is often overexpressed in many cancers. It contributes to tumor progression, metastasis and drug resistance through activating downstream signaling cascades, making it an emerging therapeutic target. The first-in-class AXL inhibitor R428 (BGB321) was approved by the FDA for the treatment of relapsed or refractory acute myeloid leukemia. R428 (B...

Prevalence of germline mutations in BRCA1/2 in patients from northeastern Brazil.
https://meetinglibrary.asco.org/record/189667
Clarissa Gondim Picanço-Albuquerque, PhD

May 28th, 2020 - Background: Identifying carriers of hereditary cancer predisposition syndromes (HCPS) improves prevention and treatment. However, due to the elevated cost of genetic testing, information on the prevalence and incidence of HCPS is scarce, depriving patients of assertive treatment―a scenario observed worldwide, especially in regions like Northeastern Brazil. In this study, we determined the preva...

An innovative, internet-based assessment of financial toxicity (FT), psychological distress, and quality of life (QOL) in ovarian cancer survivors (OCS).
https://meetinglibrary.asco.org/record/189875
Fay J. Hlubocky, PhD, MA

May 28th, 2020 - Background: FT is recognized as a significant predictor of stress for OCS on treatment yet little is known about its impact during long-time survivorship. Using an innovative, internet-based design, we assessed the prevalence of FT, psychological distress, and QOL among OCS. Methods: OCS members from the National Ovarian Cancer Coalition (NOCC) completed this web-based assessment using the foll...

Prevalence of pathogenic non-BRCA1/2 gene variants in patients with suspected hereditary breast and ovarian cancer at a referral hospital in northeastern Brazil.
https://meetinglibrary.asco.org/record/189537
Rosane Oliveira Sant'Ana, MD, PhD

May 28th, 2020 - Background: Breast cancer (BC) is associated with several hereditary syndromes (HS). Patients with clinical criteria for hereditary breast and ovarian cancer (HBOC) should be evaluated for the presence of pathogenic BRCA1/2 variants, although the absence of BRCA1/2 variants does not rule out HS. The purpose of this study was to evaluate the prevalence of pathogenic non-BRCA1/2 variants in patie...

Gynecologic oncology, gender and relevant leadership in academic medicine.
https://meetinglibrary.asco.org/record/190353
Sarah Madhu Temkin, MD

May 28th, 2020 - Background: Within academic medicine, there has been increasing attention to diversity and inclusion. We sought to characterize gynecologic oncologist (GO) faculty inclusion, with attention to gender in relevant academic leadership roles. Methods: Using the American Association of Medical Colleges list of accredited schools of medicine academic institutions were identified. Observational data w...

Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) for advanced breast cancer patients with high risk for Hereditary Breast and Ovarian Cancer Syndrome (HBOC).
https://meetinglibrary.asco.org/record/189659
Rosane Oliveira Sant'Ana, MD, PhD

May 28th, 2020 - Background: Local Advanced Breast Cancer (LABC) is associated with high risk of death. NAC is a safe and effective approach for these populations. pCR is a proven prognostic factor in several studies of NAC. HBOC is associated to high risk of breast cancer usually in young age and especially for BRCA1 mutations with a basal phenotype. The aim of this study was to evaluate the influence of BRCA ...

Trajectories of sexual dysfunction and its risk factors in women with gynecologic cancer across radiation therapy and healthy controls.
https://meetinglibrary.asco.org/record/189843
Jinbing Bai, PhD

May 28th, 2020 - Background: Women with gynecological cancer (GynCa) reported an increased risk for acute and long-term sexual dysfunction across cancer treatments, especially radiation therapy (RT). However, limited data exist on the course of sexual dysfunction across RT and its risk factors are unknown. This study sought to characterize women’s sexual dysfunction trajectories and identified risk factors of p...

Markers of a metastatic niche in the omentum in ovarian cancer.
https://meetinglibrary.asco.org/record/186113
Tatiana I. Moiseenko

May 28th, 2020 - Background: Ovarian cancer spreads intraperitoneally due to the interaction of tumor cells and the omental mesothelium, creating a metastatic niche and supporting elements of cancer cell expansion such as adhesion, proliferation, migration, and neoangiogenesis. The purpose of the study was to analyze levels of VEGFA, IGF-I, IGF-II and TGFβ1 in omental tissues in ovarian cancer (OC). Methods: Th...

Adult ovarian granulosa cell tumor: Role of systemic chemotherapy and surgical treatment.
https://meetinglibrary.asco.org/record/186107
Anna Beliaeva

May 28th, 2020 - Background: Granulosa cell tumor (GCT) are rare sex cord-stromal tumours. Their frequency is approximately 3% - 5% of all malignant ovarian tumors, and the incidence is from 0.6 to 2.1 cases per 100 000 women per year. According to the histological features, GCT are divided into two types: adult and juvenile. In the 2014 WHO histological classification, GCT were divided into borderline, which i...

Clinicopathologic and protein markers distinguishing POLE and copy-number low group in endometrial cancer.
https://meetinglibrary.asco.org/record/186103
Kidong Kim, MD, BA

May 28th, 2020 - Background: Requirement of DNA sequencing to diagnose POLE group is a barrier for adoption of molecular subtyping in endometrial cancer. We aimed to identify clinicopathologic and protein markers distinguishing POLE and copy-number (CN) low group in endometrial cancer. Methods: Ninety-one samples (POLE: 15, CN low 76) classified as POLE or CN low groups by integrative clustering were selected f...

Treatment patterns among newly diagnosed women with cervical cancer in the United States.
https://meetinglibrary.asco.org/record/186117
Anuj Shah

May 28th, 2020 - Background: To address the gap in US-based real-world data, this analysis described the real-world treatment patterns among newly diagnosed cervical cancer patients. Methods: Women newly diagnosed with cervical cancer between Jan 2015 – June 2018, with a confirmatory diagnosis or treatment within 2 months, and continuous enrollment for 12 months prior and 6 months post diagnosis were identified...

OvarianTag biomarker panel in order guide treatment decisions cisplatin-based for women with epithelial ovarian cancer.
https://meetinglibrary.asco.org/record/190893
Leticia da Conceição Braga, PhD

May 28th, 2020 - Background: Ovarian cancer (OC) represents the most lethal gynecologic cancer. Late-stage diagnosis associated with a lack of effective markers to detect chemotherapy resistance contributes to high mortality and poor prognosis of epithelial ovarian cancer (EOC). OvarianTag Biomarkers Panel was developed as biopsy-based gene expression assay to discriminate prognosis in EOC patients, to understa...

Tissue factor pathway inhibitor II as a specific biomarker for pre-operative prediction of clear-cell carcinoma of the ovary.
https://meetinglibrary.asco.org/record/190897
Etsuko Miyagi, MD, PhD

May 28th, 2020 - Background: Tissue factor pathway inhibitor 2 (TFPI2) is a novel serum biomarker that discriminates ovarian clear cell carcinomas (CCC) from borderline ovarian tumors (BD) and non-CCC epithelial ovarian cancers (EOC). We examined the prediction performances of TFPI2, including high specificity, for preoperative diagnosis of CCC in multi-center settings. Methods: We collected serum samples obtai...

Effect of the oral CXCR4 inhibitor X4-136 on tumor control and side effects in cervical cancer treated with radiotherapy and concurrent chemotherapy.
https://meetinglibrary.asco.org/record/190892
Naz Chaudary, PhD

May 28th, 2020 - Background: Cervical cancer is a global health problem. Despite scale up of prevention programs, there will be an ongoing need to improve the effectiveness of radiotherapy/cisplatin (RTCT) for women with established, locally advanced disease. We have shown that RTCT with the CXCR4 inhibitor plerixafor improves tumor control, reduces metastases and reduces RT-related side effects compared to RTC...

Prognostic significance of hormone receptor (ER/PR) status in endometrial carcinoma in black women: Implications with lymph node metastasis.
https://meetinglibrary.asco.org/record/190887
Manan Shah, MD

May 28th, 2020 - Background: Histological examination of tumor tissues is necessary for deciding if endometrial surgery should include lymph node sampling. Studies have demonstrated that loss of estrogen and progesterone receptors (ER/ PR) independently predicts lymph node metastasis and poor prognosis. African American females in comparison to their Caucasian counterparts are diagnosed at a later stage, with h...

Surface-modified nanoparticle transport evaluated in a multistage model of ovarian cancer.
https://meetinglibrary.asco.org/record/190920
Stephen Winter, M.E.

May 28th, 2020 - Background: A novel multi-stage model composed of ovarian cancer (SKOV-3) and fibroblast (MRC-5) cells was developed to provide a physiologically relevant in vitro platform to assess nanoparticle (NP) transport and aid in the development of more targeted clinical therapies. This multicellular ovarian tumor spheroid model is customized to the stages of ovarian cancer progression. The model lever...

Hrd in ovarian cancer: Defined today, evolving for the future.
https://meetinglibrary.asco.org/record/190929
Markus Eckstein

May 28th, 2020 - Background: Homologous Recombination Repair (HRR) gene mutations result in Homologous Recombination Deficiency (HRD) associated with increased risk of high grade serous ovarian (HGOC) cancer and subsequent response to PARP inhibitors (PARPi). Traditionally, HRD has been determined by testing for germline and/or somatic BRCA1/2 mutations. Today, a growing number of HRR gene mutations are known t...

A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707).
https://meetinglibrary.asco.org/record/190924
Eleftheria Kalogera, MD

May 28th, 2020 - Background: AB160 is a 160 nm nano-immunoconjugate consisting of nab-paclitaxel (NP) nanoparticles non-covalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of vascular-endothelial growth factor (VEGF). Both taxanes (GOG-0129C, GOG-0126R, GOG-0127V) and BEV (GOG-0229E, AURELIA, GOG-0227C) have demonstrated clinical activity in previously treated meta...

Efficacy and toxicity of immunotherapy with immune checkpoint inhibitors in gynecologic cancers.
https://meetinglibrary.asco.org/record/190896
Michelle Kuznicki

May 28th, 2020 - Background: There is limited data on outcomes for gynecologic cancer patients treated with immune checkpoint inhibitors (ICI) outside the scope of clinical trials. Here we present our Institutional experience with a cohort of endometrial (EC) and ovarian cancer (OC) treated with ICI. Methods: 59 patients who received ICI were included (23 OC and 36 EC). Progression-free (PFS) and Overall surviv...